氯雷他定市場 - 全球產業規模、佔有率、趨勢、機會、預測：按等級類型、過敏原類型、測試類型、地區和競爭格局分類，2021-2031年

全球氯雷他定市場預計將從 2025 年的 1.6452 億美元成長到 2031 年的 1.9979 億美元，複合年成長率為 3.29%。

氯雷他定是一種選擇性周邊組織胺受體拮抗劑，主要用於治療過敏性鼻炎和蕁麻疹，且不會引起鎮靜作用。市場成長的主要促進因素是全球過敏性疾病負擔日益加重以及消費者對易於取得的非處方藥的偏好不斷成長。此外，城市擴張和由此導致的污染加劇也起到了催化劑的作用，推動了對有效抗組織胺藥物的需求。

阻礙市場發展的主要障礙是市場飽和，因為新一代抗組織胺藥物憑藉其卓越的療效和安全性，已佔據主導地位。在這種競爭環境下，龐大的患者群仍需緩解症狀。根據美國氣喘與過敏基金會（AAFA）預測，到2024年，美國將有約1億人患有各種過敏症。雖然如此高的盛行率表明對氯雷他定等藥物的需求仍然存在，但來自先進藥物的激烈競爭，對這類藥物實現市場主導地位構成了重大挑戰。

市場促進因素

氣候變遷導致花粉季延長，顯著推高了氯雷他定的需求，因為患者需要緩解症狀的時間也隨之延長。全球氣溫上升導致許多地區的冰凍期延長，使得植物能夠更長時間、更高濃度地產生花粉。這種環境變化迫使過敏患者全年服用抗組織胺藥，而不僅僅是在傳統的過敏高峰期，導致銷售成長。根據氣候中心（Climate Central）2024年3月發布的報告《季節性過敏：花粉和黴菌》，自1970年以來，美國203個地區的冰凍期平均延長了19天。冰凍期的延長與人們持續光顧藥局以及非鎮靜性抗組織胺消費量的增加密切相關。同時，空氣品質惡化（值得注意的是，在IQAir發布的《2023年全球空氣品質報告》中，只有7個國家達到了世衛組織PM2.5標準）加劇了呼吸系統疾病，進一步支撐了市場需求。

過敏性鼻炎發生率的上升是全球氯雷他定市場的主要驅動力，不斷成長的患者群體需要持續的治療性介入。由於遺傳和環境因素的雙重影響，過敏性鼻炎的盛行率不斷上升，領先的製藥公司在過敏領域實現了持續的收入成長，這支撐了對氯雷他定等成熟藥物的持續需求。這種需求正變得越來越穩定，而不再只是季節性的，從而推動了主要市場參與者的強勁業績。例如，拜耳公司於2024年3月發布的2023會計年度年度報告顯示，經匯率和產品組合調整後，其過敏和感冒類產品的銷售額成長了7.2%。這主要得益於歐洲和北美市場的強勁需求。這一成長趨勢凸顯了過敏管理產品在消費者保健產品系列中的關鍵作用，並反映出人們越來越依賴成熟的抗組織胺藥物來維持日常生活品質。

市場挑戰

全球氯雷他定市場面臨一個重大障礙：由於新一代抗組織胺的出現，市場已趨於飽和。這些先進的藥物替代療法通常比氯雷他定具有更優的療效和安全性，包括起效更快、鎮靜作用更小。這種激烈的競爭正在阻礙市場成長，因為相當一部分患者轉向了這些現代治療方法，從而侵蝕了氯雷他定的市場佔有率，並限制了其在處方藥和非處方藥領域的收入潛力。

這種競爭飽和的影響因對有效長期治療過敏性疾病的迫切需求而進一步加劇。根據氣喘與過敏基金會預測，到2024年，過敏症將成為美國第六大慢性病死因。這項高排名凸顯了過敏症帶來的沉重健康負擔，並促使患者和醫療保健提供者積極尋求最有效、最先進的治療方案。因此，隨著慢性過敏症的普遍流行，消費者轉向最新的藥物創新，氯雷他定在保持其競爭優勢方面面臨巨大的挑戰。

市場趨勢

隨著消費者越來越傾向於選擇便利的線上平台，電子商務和數位藥局分銷管道的快速成長正在從根本上改變氯雷他定的供應方式。這種轉變幫助慢性過敏患者利用訂閱服務，確保在漫長的花粉季期間獲得穩定的抗組織胺藥物供應。數位貨架便於大宗購買比價，增強了氯雷他定直接面對消費者的銷售管道，同時也幫助主要參與者最佳化其數位化供應鏈。根據Haleon plc於2024年3月發布的2023會計年度年度報告，電子商務銷售額成長了17%，佔全球總銷售額的10%，這反映出消費者在購買自我護理產品時普遍轉向數位化管道。

消費者對價格日益敏感，推動了具成本效益學名藥市場滲透率的不斷提高，這正在顯著改變行業格局。零售商積極推廣價格更低、療效相當的自有品牌氯雷他定類藥物，提升了非專利生產商的銷售量。這一趨勢正在形成一種市場環境，在這個環境中，價格承受能力而非品牌忠誠度正在影響消費者的購買行為，並迫使原廠藥生產商在價格方面競爭。根據瑞迪博士實驗室（Dr. Reddy's Laboratories）於2024年7月發布的2023-2024會計年度年度報告，全球非專利收入達到2455億盧比，年增15%。這一成長主要得益於北美市場的強勁表現，該地區對非專利抗組織胺藥物的需求依然旺盛。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球氯雷他定市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 分級（USP標準級、EP標準級、藥用標準級）
  • 過敏原類型（食物、吸入物、藥物、其他）
  • 依測試類型（體外測試、體外測試）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美氯雷他定市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲氯雷他定市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區氯雷他定市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：氯雷他定在中東和非洲的市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美氯雷他定市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球氯雷他定市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• R-Biopharm AG
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• GSK plc
• bioMerieux, Inc.
• Danaher Corporation
• Thermo Fisher Scientific Inc.
• Siemens Healthineers AG
• AbbVie Inc.
• Pfizer Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Loratadine Market is projected to expand from USD 164.52 Million in 2025 to USD 199.79 Million by 2031, registering a compound annual growth rate (CAGR) of 3.29%. Functioning as a selective peripheral histamine receptor antagonist, loratadine is primarily utilized for treating allergic rhinitis and urticaria without inducing sedative effects. The market's growth is fundamentally driven by the escalating global burden of allergic conditions and a rising consumer preference for readily accessible nonprescription medications. Furthermore, the expansion of urban environments and the associated increase in pollution levels act as catalysts, intensifying the demand for effective antihistamine treatments.

A significant obstacle hindering market progression is the saturation of the sector by newer generation antihistamines that boast superior efficacy and safety profiles. This competitive environment persists alongside a vast patient demographic requiring symptom relief. According to the Asthma and Allergy Foundation of America, approximately 100 million people in the United States lived with various types of allergies in 2024. While this substantial prevalence highlights the continued necessity for drugs like loratadine, the fierce competition from advanced pharmacological alternatives remains a critical barrier to achieving market dominance.

Market Driver

Prolonged pollen seasons resulting from climate change are significantly bolstering the demand for loratadine by extending the periods during which patients require symptomatic relief. As global temperatures rise, freeze-free intervals in many regions are widening, enabling plants to produce pollen for longer windows and often at higher intensities. This environmental shift compels allergy sufferers to use antihistamines for extended durations throughout the year rather than solely during traditional peak months, thereby increasing unit sales volume. According to Climate Central's March 2024 report, 'Seasonal Allergies: Pollen and Mold,' the freeze-free growing season has lengthened by an average of 19 days across 203 locations in the United States since 1970. This extension correlates with sustained pharmacy visits and consumption of non-sedating antihistamines, while worsening air quality-highlighted by IQAir's 'World Air Quality Report 2023' where only seven countries met WHO PM2.5 guidelines-synergistically aggravates respiratory conditions, broadly supporting market intake.

The increasing prevalence of allergic rhinitis serves as a foundational driver for the Global Loratadine Market, necessitating consistent therapeutic intervention for a growing patient base. As incidence rates climb due to both genetic and environmental factors, major pharmaceutical manufacturers are recording sustained revenue growth in their allergy segments, validating the ongoing need for proven molecules like loratadine. This demand is not merely seasonal but increasingly perennial, driving robust performance for key market players. For instance, Bayer AG's 'Annual Report 2023', released in March 2024, reported a 7.2 percent increase in sales within the Allergy & Cold category on a currency- and portfolio-adjusted basis, driven largely by high demand in Europe and North America. This upward trend underscores the critical role of allergy management products in consumer healthcare portfolios and reflects the expanding reliance on established antihistamine treatments to manage daily quality of life.

Market Challenge

The Global Loratadine Market faces a formidable obstacle due to the saturation of the sector by newer generation antihistamines. These advanced pharmacological alternatives often present superior efficacy and safety profiles, such as a faster onset of action and reduced sedative effects compared to loratadine. This intense competition hampers market growth by diverting a significant portion of the patient population toward these modern therapies, thereby eroding loratadine's market share and limiting its revenue potential in both prescription and over-the-counter segments.

The impact of this competitive saturation is magnified by the critical need for effective long-term management of allergic conditions. According to the Asthma and Allergy Foundation of America, in 2024, allergies ranked as the sixth leading cause of chronic illness in the United States. This high ranking underscores the severity of the health burden, compelling patients and healthcare providers to aggressively seek out the most potent and advanced treatment options available. Consequently, loratadine faces significant headwinds in retaining its dominance as the widespread prevalence of chronic allergies drives consumers toward the latest pharmacological innovations.

Market Trends

The rapid growth of e-commerce and digital pharmacy distribution channels is fundamentally reshaping loratadine accessibility, as consumers increasingly prefer online platforms for convenience. This shift supports chronic allergy sufferers who utilize subscription services to ensure steady antihistamine supplies during extended pollen seasons. Digital shelves facilitate bulk-pack comparisons, strengthening the molecule's direct-to-consumer presence while allowing major players to optimize digital supply chains. According to Haleon plc's 'Annual Report 2023' from March 2024, e-commerce sales grew by 17 percent to account for 10 percent of total global sales, reflecting the widespread migration toward digital procurement for self-care products.

The rising market penetration of cost-effective generic alternatives is significantly altering the sector, driven by heightened consumer price sensitivity. Retailers are aggressively promoting private-label loratadine that offers identical therapeutic benefits at reduced costs, thereby fueling volume growth for generic manufacturers. This trend creates a market environment where affordability dictates consumption patterns over brand loyalty, pressuring original formulators to compete on value. According to Dr. Reddy's Laboratories' 'Annual Report 2023-24' released in July 2024, revenue from the Global Generics segment reached Rs. 245.5 billion, a 15 percent growth largely driven by strong performance in North America where generic antihistamine uptake remains robust.

Key Market Players

• R-Biopharm AG
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• GSK plc
• bioMerieux, Inc.
• Danaher Corporation
• Thermo Fisher Scientific Inc.
• Siemens Healthineers AG
• AbbVie Inc.
• Pfizer Inc.

Report Scope

In this report, the Global Loratadine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Loratadine Market, By Grade Type

• USP Standard Grade
• EP Standard Grade
• Medicine Standard Grade

Loratadine Market, By Allergen Type

• Food
• Inhaled
• Drug
• Others

Loratadine Market, By Test Type

• In-vivo test
• In-vitro test

Loratadine Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Loratadine Market.

Available Customizations:

Global Loratadine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Loratadine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Grade Type (USP Standard Grade, EP Standard Grade, Medicine Standard Grade)
  • 5.2.2. By Allergen Type (Food, Inhaled, Drug, Others)
  • 5.2.3. By Test Type (In-vivo test, In-vitro test)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Loratadine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Grade Type
  • 6.2.2. By Allergen Type
  • 6.2.3. By Test Type
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Loratadine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Grade Type
      • 6.3.1.2.2. By Allergen Type
      • 6.3.1.2.3. By Test Type
  • 6.3.2. Canada Loratadine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Grade Type
      • 6.3.2.2.2. By Allergen Type
      • 6.3.2.2.3. By Test Type
  • 6.3.3. Mexico Loratadine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Grade Type
      • 6.3.3.2.2. By Allergen Type
      • 6.3.3.2.3. By Test Type

7. Europe Loratadine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Grade Type
  • 7.2.2. By Allergen Type
  • 7.2.3. By Test Type
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Loratadine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Grade Type
      • 7.3.1.2.2. By Allergen Type
      • 7.3.1.2.3. By Test Type
  • 7.3.2. France Loratadine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Grade Type
      • 7.3.2.2.2. By Allergen Type
      • 7.3.2.2.3. By Test Type
  • 7.3.3. United Kingdom Loratadine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Grade Type
      • 7.3.3.2.2. By Allergen Type
      • 7.3.3.2.3. By Test Type
  • 7.3.4. Italy Loratadine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Grade Type
      • 7.3.4.2.2. By Allergen Type
      • 7.3.4.2.3. By Test Type
  • 7.3.5. Spain Loratadine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Grade Type
      • 7.3.5.2.2. By Allergen Type
      • 7.3.5.2.3. By Test Type

8. Asia Pacific Loratadine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Grade Type
  • 8.2.2. By Allergen Type
  • 8.2.3. By Test Type
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Loratadine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Grade Type
      • 8.3.1.2.2. By Allergen Type
      • 8.3.1.2.3. By Test Type
  • 8.3.2. India Loratadine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Grade Type
      • 8.3.2.2.2. By Allergen Type
      • 8.3.2.2.3. By Test Type
  • 8.3.3. Japan Loratadine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Grade Type
      • 8.3.3.2.2. By Allergen Type
      • 8.3.3.2.3. By Test Type
  • 8.3.4. South Korea Loratadine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Grade Type
      • 8.3.4.2.2. By Allergen Type
      • 8.3.4.2.3. By Test Type
  • 8.3.5. Australia Loratadine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Grade Type
      • 8.3.5.2.2. By Allergen Type
      • 8.3.5.2.3. By Test Type

9. Middle East & Africa Loratadine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Grade Type
  • 9.2.2. By Allergen Type
  • 9.2.3. By Test Type
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Loratadine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Grade Type
      • 9.3.1.2.2. By Allergen Type
      • 9.3.1.2.3. By Test Type
  • 9.3.2. UAE Loratadine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Grade Type
      • 9.3.2.2.2. By Allergen Type
      • 9.3.2.2.3. By Test Type
  • 9.3.3. South Africa Loratadine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Grade Type
      • 9.3.3.2.2. By Allergen Type
      • 9.3.3.2.3. By Test Type

10. South America Loratadine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Grade Type
  • 10.2.2. By Allergen Type
  • 10.2.3. By Test Type
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Loratadine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Grade Type
      • 10.3.1.2.2. By Allergen Type
      • 10.3.1.2.3. By Test Type
  • 10.3.2. Colombia Loratadine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Grade Type
      • 10.3.2.2.2. By Allergen Type
      • 10.3.2.2.3. By Test Type
  • 10.3.3. Argentina Loratadine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Grade Type
      • 10.3.3.2.2. By Allergen Type
      • 10.3.3.2.3. By Test Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Loratadine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. R-Biopharm AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Teva Pharmaceutical Industries Ltd.
• 15.3. Sun Pharmaceutical Industries Ltd.
• 15.4. GSK plc
• 15.5. bioMerieux, Inc.
• 15.6. Danaher Corporation
• 15.7. Thermo Fisher Scientific Inc.
• 15.8. Siemens Healthineers AG
• 15.9. AbbVie Inc.
• 15.10. Pfizer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer